Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$23.41 USD
+0.68 (2.99%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $23.47 +0.06 (0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BCYC 23.41 +0.68(2.99%)
Will BCYC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
Other News for BCYC
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Bicycle Therapeutics Announces Board Reshuffle and New Financial Agreement
Expert Ratings For Bicycle Therapeutics
Analysts Conflicted on These Healthcare Names: Tilray (TLRY), Hologic (HOLX) and Bicycle Therapeutics (BCYC)
Bicycle Therapeutics: Strong Buy on Breakthrough Preclinical Data, Clinical Progress, and Robust Financial Health